A prospective study on safety and clinical efficacy of rabies biologicals in paediatric patients with category III animal exposure.

Nidhi Fotedar, Haradanahalli Shankaraiah Ravish
Author Information
  1. Nidhi Fotedar: Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India. ORCID
  2. Haradanahalli Shankaraiah Ravish: Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India. ORCID

Abstract

Purpose: Rabies remains a significant public health concern worldwide, particularly among paediatric populations who are vulnerable to animal exposures. This prospective study aimed to assess the safety and clinical efficacy of rabies biologicals in pediatric patients following category III animal exposures.
Materials and Methods: A prospective study was undertaken enrolling 289 pediatric patients fulfilling eligibility criteria who presented with category III animal exposures at the anti-rabies clinic of Kempegowda Institute of Medical Sciences Hospital and Research Centre, Bangalore. All the subjects received rabies biologicals as per National Centre for Disease Control guidelines. The details pertaining to socio-demographic profile, biting animal, characteristics of wound, and details of post-exposure prophylaxis (PEP) provided were recorded. All the study subjects were followed up for immediate and delayed adverse events (AEs). Subsequently, all were followed up for 6 months to demonstrate the clinical efficacy of PEP.
Results: The mean age of study subjects was 9.4 years, and most of them (43%) were going to school. Dog was the predominant biting animal (96.6%) with most bites being abrasions (45%), mainly on the lower limbs (42%). Single rabies monoclonal antibody was the most commonly administered passive immunization (67%), and purified Vero cell rabies vaccine was the predominant vaccine (65%). AEs following PEP were primarily local, predominantly pain (13.2%), and there were no systemic events. All the subjects were alive and healthy at the end of 6 months following PEP.
Conclusion: This study contributes valuable insights into the safety and clinical efficacy of rabies biologicals in a pediatric cohort following category III animal exposures, supporting the continued use of these biologicals in pediatric patients.

Keywords

References

  1. Hum Vaccin Immunother. 2018;14(11):2660-2665 [PMID: 29771638]
  2. Vaccine. 2019 Oct 3;37 Suppl 1:A88-A93 [PMID: 30471958]
  3. BMC Public Health. 2018 Aug 9;18(1):996 [PMID: 30092769]
  4. Lancet Neurol. 2002 Jun;1(2):101-9 [PMID: 12849514]
  5. Hum Vaccin Immunother. 2021 Aug 3;17(8):2554-2559 [PMID: 33621471]
  6. Indian J Community Med. 2024 Mar-Apr;49(2):443-447 [PMID: 38665446]
  7. Hum Vaccin Immunother. 2021 Jul 3;17(7):2090-2096 [PMID: 33563087]
  8. Lancet Infect Dis. 2025 Jan;25(1):126-134 [PMID: 39362224]
  9. J Commun Dis. 2006 Dec;38(4):355-61 [PMID: 17913213]
  10. Hum Vaccin Immunother. 2022 Nov 30;18(5):2081024 [PMID: 35687876]
  11. Vaccine. 2005 Feb 25;23(14):1709-14 [PMID: 15705476]
  12. Virusdisease. 2018 Sep;29(3):362-368 [PMID: 30159372]
  13. Bull World Health Organ. 2005 May;83(5):360-8 [PMID: 15976877]
  14. PLoS Negl Trop Dis. 2015 Apr 16;9(4):e0003709 [PMID: 25881058]
  15. Clin Infect Dis. 2021 Nov 2;73(9):e2722-e2728 [PMID: 32556113]
  16. Int J Infect Dis. 2007 Jan;11(1):29-35 [PMID: 16678463]
  17. Vaccines (Basel). 2023 Mar 29;11(4): [PMID: 37112668]
  18. World Health Organ Tech Rep Ser. 2013;(982):1-139, back cover [PMID: 24069724]
  19. Hum Vaccin Immunother. 2021 Dec 2;17(12):5355-5360 [PMID: 35061550]
  20. Lancet. 2014 Oct 11;384(9951):1389-99 [PMID: 24828901]
  21. Trop Med Int Health. 2016 Apr;21(4):556-63 [PMID: 26799375]

Word Cloud

Created with Highcharts 10.0.0animalstudyrabiesbiologicalsexposuresclinicalefficacypediatricpatientsfollowingcategoryIIIsubjectsPEPprospectivesafetyRabiespaediatricCentredetailsbitingfollowedeventsAEs6monthspredominantvaccineexposurePurpose:remainssignificantpublichealthconcernworldwideparticularlyamongpopulationsvulnerableaimedassessMaterialsMethods:undertakenenrolling289fulfillingeligibilitycriteriapresentedanti-rabiesclinicKempegowdaInstituteMedicalSciencesHospitalResearchBangalorereceivedperNationalDiseaseControlguidelinespertainingsocio-demographicprofilecharacteristicswoundpost-exposureprophylaxisprovidedrecordedimmediatedelayedadverseSubsequentlydemonstrateResults:meanage94years43%goingschoolDog966%bitesabrasions45%mainlylowerlimbs42%Singlemonoclonalantibodycommonlyadministeredpassiveimmunization67%purifiedVerocell65%primarilylocalpredominantlypain132%systemicalivehealthyendConclusion:contributesvaluableinsightscohortsupportingcontinueduseAnimalEfficacyPediatricSafety

Similar Articles

Cited By